Elexacaftor-Tezacaftor- Ivacaftor improves sinonasal outcomes in cystic fibrosis

Improvement in sinonasal quality‐of‐life indicators for pediatric patients with cystic fibrosis treated with elexacaftor‐tezacaftor‐ivacaftor

“…Limited data in adults reveal an association between ITE therapy and improved sinonasal quality of life. [3][4][5] This study evaluates the effect of ITE therapy on smell threshold and discrimination, quality of life, and self-reported respiratory function as measured by the Cystic Fibrosis Questionnaire-Revised (CFQ-R) and Sinonasal Outcomes Test (SNOT-22) in a cohort of pediatric patients with CF at Children's Hospital Los Angeles (CHLA). behalf.…”

“…Trikafta is a combination of three CF transmembrane receptor (CFTR) modulators, a potentiator (ivacaftor) and two correctors (tezacaftor and elexacaftor) (ITE therapy), that work in concert to optimize production and function of the CFTR protein. Limited data in adults reveal an association between ITE therapy and improved sinonasal quality of life 3–5 . This study evaluates the effect of ITE therapy on smell threshold and discrimination, quality of life, and self‐reported respiratory function as measured by the Cystic Fibrosis Questionnaire‐Revised (CFQ‐R) and Sinonasal Outcomes Test (SNOT‐22) in a cohort of pediatric patients with CF at Children's Hospital Los Angeles (CHLA).…”

Objective and patient‐based measures of chronic rhinosinusitis in people with cystic fibrosis treated with highly effective modulator therapy

“…HEMT improves CRS in PwCF across both patientreported and objective measures of disease. 2,9 Despite improvement in multiple outcomes, no correlations were observed between improvements in sinonasal symptoms and radiologic findings. This finding was unanticipated given the robust improvements seen with ETI in this cohort.…”

Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis

“…A correlation between all lung function parameters and MRI outcomes was observed [ 66 ]. Another observational study was performed by Stapleton and collaborators to assess the effects of ETI therapy on sinonasal symptoms of 34 adults with CF (average age of 27 years, 67% homozygous for F508del-CFTR) [ 67 ]. Data revealed improved symptoms, such as endoscopic crust, significantly reduced nasal polyps, muconasal thickening, and sinus opacity rapidly and durably for at least 180 days on ETI therapy [ 67 ].…”